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This review is aimed at discussing the role of voltage gated sodium channels 
(VGSC) Nav 1.8 and 1.9 in pain states. This involves establishing their role in 
pain states such as neuropathic and inflammatory pain, and which of these 
pain states the individual channels impact on and to what effect. Establishing 
this will involve an exploration of which neurones these channels are located 
around the body, sensory or nociceptive, as well how their activity impacts on 
their function. Also discussed will be how the routes of activation of these 
VGSC impacts on their role in pain sensation and detection within the 
neurones in which they are found. This will be achieved by the analysis of 
studies and investigations collected spanning a 30-year period. These 
experiments use many different techniques that can be compared to draw a 
strong conclusion on the role of Nav 1.8 and 1.9. This will be used to indicate 
possible uses of this knowledge in the medical fields such as anaesthesia, 






















What are voltage gated sodium channels? 
Voltage gated sodium channels are complex transmembrane proteins that 
allow the rapid flow of sodium ions across the membrane creating a current 
that is involved in the depolarising upstroke of an action potential generated in 
an excitable sensory neurone (Cummins et al, 2007).  
 
The basic structure of the VGSC are a large α subunit which carries the 
functional capacity, accompanied by one or two smaller ancillary β subunits 
which have chaperone characteristics in that they stabilise the α subunit 
(Okuse et al 2002). The α subunit is comprised of four domains all of which 
are themselves made up of six segments, which all interact to provide function 
to the channel. Conformational changes in the S4 segment on all four 
domains of the α subunit alter the state of the channel between inactive, 
closed and open states and thus controlling the flow of the sodium current 
(Amir et al 2006).  
 
Tetrodotoxin (TTX) is a substance from the liver of puffer fish (Cummins et al 
2007; Amaya et al 2000), which is used to categories two groups within the 
isoforms of VGSC. An isoform is defined as sensitive to TTX (TTX-s) if its 
current is inhibited at a concentration of less than 1 μMol, and resistant (TTX-
r) if it takes a higher concentration for inhibition (Elliott and Elliott 1993; 
Kostyuk et al 1981). Although both these papers are dated the work they 
detail is of huge importance and the correlation between the findings 
reinforces the conclusion of each in providing a base for further development. 
TTX-s VGSC are the channels: 1.1-1.4 and 1.6, 1.7; channels 1.5 and 1.8, 1.9 
are all the TTX-r channels (Amir et al 2006).  The ability to divide between the 
nine sodium channel isoforms currently known about has been vital to 
understanding the role of each of the channels in the body. This breakdown 
into individual channels was possible due to characterisation of each channels 
electrophysiological characteristic, for example matching up sodium current 
with the channel responsible for generation of that current (Golden, 2001; 
Goldin et al, 2000). This research development shows the advances of further 
work carried out on the original findings of Elliott and Elliot 1993; Kostyuk et al 
1981, as without these classifications and categories of the sodium channels 
it would not be possible to identify individual channels and their roles in the 
body. 
 
Where are they located? 
 This work is focused on the role of VGSC 1.8 and 1.9, formally known as 
SNS and SNS2 respectively, which are TTX-r. TTX-r sodium currents were 
found originally primarily in the subpopulation of small diameter sensory 
neurons though to be involved in nociception (Caffery et al, 1992; Roy and 
Narahashi, 1992; Elliott and Elliott, 1993). This work was further advanced 
and reinforced when the TTX-r current was found to dominate the Aδ and C 
fibres (Gold et al 2003; Amaya et al 2000; Padilla et al 2007), shown to be 
thermo receptors and nociceptors (Amaya et al 2000). This is key as six 
independent studies have all concluded the presence of TTX-r current in 
neurones confirmed as nociceptive, This has strong implications that TTX-r 
VGSC 1.8 and 1.9 do have a role in the sensation and detection of noxious 
stimuli, and the initiation of nociceptor activity in pain states; or they would be 




found at a higher proportion in non nociceptive sensory neurones. The VGSC 
1.8 and 1.9 are found in the peripheral nerve endings of neurones as well as 
the dorsal root and trigeminal ganglions (Padilla et al 2007); this implies they 
could influence peripheral and central sensitisation of C and Aδ nociceptors 
(Woolf 2004). This is supported by findings that many C fibres expressing 1.8 
or 1.9 co-express TRPV1, the capsaicin receptor formally known as VR1 
(Tominaga et al 1998; Caterina et al 1997). TRPV1 is the receptor for noxious 
thermal stimuli, and thus is strong support that VGSC 1.8 and 1.9 are involved 
in nociceptive processing’s, due to the co- localisation.  
 
However this support is countered by findings that only forty percent of 1.9 
expressing trigeminal nociceptors co- express TRPV1 (Padilla et al 2007), a 
finding supported by Amaya et al 2000, who showed the presence of small 
TRPV1 expressing neurones which expressed neither 1.8 or 1.9 VGSC. This 
would suggest that 1.8 and 1.9 are not fundamental to sensitising thermal 
hypersensitivity, which would see a one hundred percent co- localisation thus 
limiting any contribution they would make to a pain state.  
 
On the other hand co- expression to a level of forty percent does suggest a 
certain level of involvement in themal nociceptor activity. This is supported by 
findings that all 1.8 expressing neurones are trkA positive, many of which also 
express TRPV1 along with 1.9 (Amaya et al 2000).  
 
This is also substantial support for the role of 1.8 VGSC in pain states as trkA 
is involved in peptiderigic nociceptors expressing CGRP, and are intimately 
linked with inflammatory pain (Woolf et al 1994). 
 
Despite not showing a one hundred percept co-expression of 1.9 with trkA, 
Amaya et al 2000 did show no co-localisation of the 1.9 VGSC with NF200, 
found in non- nociceptive sensory neurones, again supporting the role of 1.9 
in nociception. These findings went on to show that 1.8 could co-localise with 
NF200, suggesting a possible role in conditions such as allodynia, when 
considered with co- localisation of trkA. Allodynia occurs when a stimulus, 
which is not normally detected as noxious, is able to initiate a nociceptive 
response, for example touching sunburn. 
  
How are they activated? 
Activation of VGSC is as the name suggests due to transmembrane 
potentials. Lysine and threonine, which are positively charged amino acids, 
are in large number in the S4 'sensory' regions of all four domains in the α 
chain of the sodium channel. These S4 regions are influenced by changes in 
the transmembrane electric field surrounding the channel and thereby induce 
their purpose as the voltage sensory region, conferring open, closed or 
inactive states (Priest and Hunter 2006; Amir et al 2006). 
 
Due to the individual electrophysiological properties of the channels, the 
voltage required to open each channel is different. VGSC 1.9 for example is 
active at resting membrane potential of around -60 and -70 mV meaning it 
cannot individually provoke an action potential, but plays a role in contributing 
to sub threshold electro-genesis in the neurone (Cummins et al 1999; Herzog 




et al 2001). This means although VGSC 1.9 does not initiate a depolarising 
upswing of an action potential it does play a role in raising the resting 
membrane excitability and thus reducing the activation threshold of the 
nociceptors, which they have been shown to localise. This again suggests a 
role of Nav 1.9 in sensitisation of the nociceptor.  
 
In response to tissue or nerve injury the body releases inflammatory 
mediators such as TNFα, PGE2 and bradykinin, as part of a normal immune 
response. These inflammatory mediators are known to interact with and 
sensitise nociceptors in the periphery and can lead to peripheral and central 
sensitisation (Opree and Kress 2000). This is done by PGE2 by binding to 
trkA expressed on the nociceptor activating cAMP, and up regulating PKA and 
PKC. PKA and PKC cause phosphorylation of the proteins lysine and 
threonine, causing post translational modification and a resultant change in 
activity of receptors and ion channels in the neurone they localise, such as 
TRPV1 and VGSC 1.9 in nociceptors. Clinical evidence of this is PKA 
phosphorylation causes a reduction in the activation threshold of the TTXr 
sodium voltage gated channels, thus increasing their activity; which are 
involved in nociception (England et al 1996). This shows that inflammatory 
mediators lead to the phosphorylation of sensory receptors and ion channels 
and thus increase neuronal excitability; this could initiate an action potential 
assisted by the increased activity of 1.8 and 1.9 (Amaya et al 2006; Gold et al 
1996; 1998; 2002). This reinforces the role of Nav 1.8 and 1.9 in inflammatory 
pain, as they are both present in nociceptors and activated by the 
inflammatory mediators that sensitise them.  
 
This is supported by work which shows that inflammatory mediators sensitise 
the peripheral terminals of nociceptors by reducing the transducer channel 
threshold needed for an action potential, being the increase in VGSC activity 
(Julius and Basbaum 2001; England et al 1996). This supports the role of 
VGSC 1.8 and 1.9, as other findings suggested that only 1.8 VGSC could 
actually assist the generation of action potential, and that 1.9 contributed little 
to propagation of an action potential spike (Amir et al 2006). 
 
However when inflammatory mediators cause the phosphorylation and 
therefore change in VGSC activity, this contributes to a decreased activation 
threshold by raising the baseline membrane excitability level involving Nav 1.9 
(Amir et al 2006). This idea fits with studies that show Nav 1.9 to have slow 
activation and inactivation kinetics (Priest et al 2005), suggesting a role in 
sensitisation, as the activation threshold of the nociceptor has been lowered, 
and can remain after the immediate inflammatory response.  
 
Nav 1.8 however has properties suggesting a possible role in the sustained 
neuronal firing during neuropathic conditions, again due to slow activation 
inactivation kinetics; Nav 1.8 is able to assist with the spike initiation of an 
action potential (Rush et al 1998; Amir et al 2006).  
 
Further evidence in activation kinetics for the role of 1.9 in nociception is that 
nerve growth factor (NGF) is shown to increase both the activity of Nav 1.9, 
by phosphorylation, but also by increasing the number of the channels 




expressed in the neurone (Gold et al 1996). This increase in channel 
expression was demonstrated by the discovery of C fibres that are normally 
'silent'. These fibres become activated by the inflammatory soup released in 
response to injury, and behave just as all other C fibre nociceptors, except 
they have a ninety percent expression of Nav 1.9 (Amir et al 2006). 
 
 All these studies demonstrate the role of inflammatory mediators in 
increasing the TTX-r current form VGSC 1.8 and 1.9 providing strong 
evidence of their involvement peripheral terminal hypersensitivity, and a role 
in inflammatory pain states (Gold 1999).  
 
These studies, through the involvement of inflammatory mediators, all suggest 
that Nav 1.8 and 1.9 are involved in inflammatory pain but do not supply much 
evidence of neuropathic pain. This idea that Nav 1.8 and 1.9 are only involved 
in inflammatory pain fits with the work described above which suggest a 
critical role of inflammatory mediators in the mediation and control of the 
activity of the Nav 1.8 and 1.9. This is supported by work which finds that Nav 
1.8 is not involved in neuropathic pain, which is pain incurred when no 
noxious external stimuli is present, (Kerr et al 2001; Nassar et al 2005). 
However, other works show that 1.8 anti- sense oligonucleotides have an anti 
hypersensitivity role following nerve injury (Lai et al 2002). This does suggest 
a role of Nav 1.8 and possibly 1.9 in neuropathic pain. This may be explained 
by the slow activation and inactivation kinetics of the channels as described 
by Priest et al 2005. This may be because the activity of the Nav 1.8 and 1.9 
is maintained long after the inflammatory mediators that cause the modulation 
of their activity; and are therefore still sensitising the nociceptor, thus 
providing hypersensitivity in neuropathic conditions, then they are active.   
 
What are the uses of this work? 
One use of this data in medical terms is that blockage of the channels Nav 1.8 
decreases the nociceptive behavioural response to noxious stimuli both 
thermal and mechanical (Akopian et al 1999). This is also shown with Nav 1.9 
were null mice were shown to display around a fifty percent drop in response 
to inflammatory pain (Priest et al 2005). This reinforces the earlier statement 
that Nav 1.8 and 1.9 are in involved in pain sates with direct effects.  
 
Several studies also suggest that blocking Nav 1.8 and 1.9 may have longer-
term effects on nociception, by reducing sensitisation. As has been discussed, 
persistent hyperalgesia caused by this shows a clear role of Nav 1.9 in 
thermal nociception. This is supported by Leo et al 2009, who show Nav 1.8 
and 1.9 could play a role in thermal allodynia in neuropathic states. The role 
of Nav 1.8 in mechanical pain, such as contact with a hard surface, is 
demonstrated by anti- sense oligonucleotides that, as discussed reduce 1.8 
expression, and could reverse mechanical allodynia  
 
Inflammatory induced hypersensitivity reduction by inhibiting or blocking 
VGSC is also shown by Amaya et al 2006; who showed a reduced 
hypersensitivity induced by inflammatory mediator bradykinin, and from 
capsaicin, the activator of thermal receptors. In both tests wild type mice 




showed a much greater hypersensitivity reaction to the stimuli than the Nav 
1.9 null mice being tested on. 
 
This is clear support for the role of Nav 1.9 in hypersensitivity as well as a 
clear indication of a treatment perspective of inhibiting the action of VGSC.  
 
These findings support the work of Lai et al 2002, who showed the role of Nav 
1.8 in hypersensitivity, using antisense oligonucleotides; a technique of 
blocking the function of a strand of mRNA. This is a technique also used by 
Gold et al 2003 who also showed a loss of Nav 1.8 leads to a reduction in 
allodynia and hyperalgesia.  
 
The role of Nav 1.8 and 1.9 appears to span across multiple pain categories, 
such as thermal and mechanical. PGE2, able to produce thermal hyperalgesia 
in wild type mice is not able to induce the same effects to a significant level in 
Nav 1.9 null mice (Priest et al 2005)  
 
This is supported by Coggeshall et al 2004 and Khasar et al 1998, who 
proposed and demonstrated that 1.8 and 1.9 mediating sensory neurones 
might be an underlying factor in inflammatory hyperalgesia. This is shown by 
anti- sense KO of Nav 1.8 resulting in an increase in the base threshold to 
nociceptive stimuli, therefore reducing hyperalgesia as the membrane 
excitability drops. This is demonstrated by studies that show use of anti- 
sense KO 1.8 blocks the development of hyperalgesia from PGE2. PGE2 
release is also accompanied by an up regulation of Nav 1.8 in the DRG 
reinforcing a role in sensitisation, as PGE2 is aimed at sensitising the target 
neurone and allowing for an action potential, which appears to involve 
VGSC's. This is demonstrated by studies that show use of anti- sense KO 1.8 
blocks the development of hyperalgesia from PGE2 (Amir et al 2006). This is 
supported by Coggeshall et al 2004 and Khasar et al 1998, who proposed and 
demonstrated that 1.8 and 1.9 mediating sensory neurones might be an 
underlying factor in inflammatory hyperalgesia. This is shown by anti- sense 
KO of Nav 1.8 resulting in an increase in the base threshold to nociceptive 
stimuli, therefore reducing hyperalgesia as the membrane excitability drops 
(Coggeshall et al 2004).  
 
Inflammatory induced hypersensitivity reduction by inhibiting or blocking 
VGSC is also shown by Amaya et al 2006; who showed a reduced 
hypersensitivity induced by inflammatory mediator bradykinin, and from 
capsaicin, the activator of thermal receptors. In both tests wild type mice 
showed a much greater hypersensitivity reaction to the stimuli than the Nav 
1.9 null mice being tested on. 
 
This is clear support for the role of Nav 1.9 in hypersensitivity as well as a 
clear indication of a treatment perspective of inhibiting the action of VGSC.  
 
These findings support the work of Lai et al 2002, who showed the role of Nav 
1.8 in hypersensitivity, using antisense oligonucleotides; a technique of 
blocking the function of a strand of mRNA. This is a technique also used by 




Gold et al 2003 who also showed a loss of Nav 1.8 leads to a reduction in 
allodynia and hyperalgesia.  
 
The role of Nav 1.8 and 1.9 appears to span across multiple pain categories, 
such as thermal and mechanical. PGE2, able to produce thermal hyperalgesia 
in wild type mice is not able to induce the same effects to a significant level in 
Nav 1.9 null mice (Priest et al 2005). This shows a clear role of Nav 1.9 in 
thermal nociception. This is supported by Leo et al 2009, who show Nav 1.8 
and 1.9 could play a role in thermal allodynia in neuropathic states. The role 
of Nav 1.8 in mechanical pain, such as contact with a hard surface, is 
demonstrated by anti- sense oligonucleotides that, as discussed reduce 1.8 
expression, and could reverse mechanical allodynia (Dong et al 2007). 
 
Conclusion 
In conclusion the work described here shows a clear involvement on both Nav 
1.8 and 1.9 in pain states. This is shown by the numerous studies showing 
their localisation in nociceptive fibres both C and Aδ (Gold et al 2003; Amaya 
et al 2000). These channels were also shown to co- localise with trkA and 
TRPV1 both of which are shown to be involved in nociception (Tominaga et al 
1998; Amaya et al 2000), thus supporting a role of Nav 1.8 and 1.9 in this 
area. This work then went on to show that the involvement of inflammatory 
mediators such as bradykinin and PGE2 are strong implications of 
involvement in inflammatory pain. This was shown by an up regulation of the 
channels Nav 1.8 and 1.9 when in the presence of the mediators, both in 
number of channels expressed and excitability of those channels. The role 
that the channels play is also indicated by the action of the inflammatory 
mediators, as they cause phosphorylation of the α subunit. This 
phosphorylation is the same form of action they make on other parts of a 
sensory neurone when inducing sensitisation via changes in structure of 
receptors. This leads to implications of the role of Nav 1.9 especially as well 
as 1.8 in sensitisation of the nociceptive sensory neurones, something 
supported by the slow activation and inactivation kinetics of the channels 
(Priest et al 2005). These slow activation and inactivation kinetics play a role 
in sensitisation, and leads to a possible role in neuropathic pain, as the action 
of the channel may out last the duration of the inflammatory mediators. 
Therefore the VGSC may still be sensitising the nociceptor after the 
inflammatory response has run its course, thus contributing to neuropathic 
pain. 
 
This leads to possible medical advances due to this knowledge, as blocking of 
the Nav channels using anti- sense knockdowns leads to reduced 
hypersensitivity which could have uses in anaesthetics used in hospitals. This 
could be useful in reducing possible allodynia following surgery or a serious 
wound.  Another area of use for this knowledge is in drug treatments for 
inflammatory and potentially neuropathic pain states and conditions, for 
example rheumatoid arthritis. Here the treatment could potentially be used to 
alleviate symptoms of allodynia resulting from progressive joint destruction.  
 
However the work analysed here is not strong enough to conclude a clear use 
of Nav 1.8 and 1.9 inhibition in neuropathic pain, suggesting further work is 




needed to reinforce this conclusion, before being put into practical use. This is 
due to the disagreement between sources such as Kerr et al 2001 and Dong 
et al 2007 who contradict each other on the involvement of Nav 1.8 and 1.9 in 
neuropathic pain conditions. This level of controversy is not present in the 
involvement of Nav 1.8 and 1.9 in inflammatory pain, which all sources 
investigated seem to support allowing for an strong conclusion to be drawn, 
reinforces potential uses such as in drug treatments.
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